Dogwood Therapeutics Inc

NASDAQ:DWTXUnited States

NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

Dogwood Therapeutics, Inc., formerly Virios Therapeutics, Inc., is focused on the clinical development of three assets, Halneuron, IMC-1, and IMC-2. Halneuron is in Phase 2b development as a non-opioid, Nav 1.7 inhibitor, to treat the neuropathic pain associated with chemotherapy treatment. Halneuron is an injectable formulation of Tetrodotoxin, a novel small molecule with action exclusively on the peripheral nervous system. IMC-2 (valacyclovir + celecoxib) is in Phase 2 development as a combination antiviral treatment for Long-COVID (LC). IMC-1 (famciclovir (FM) + celecoxib) is Phase 3 development ready as a combination antiviral treatment for FM. IMC-1 has been granted fast track designation by the FDA. IMC-1 is a novel, proprietary, fixed dose combination of famciclovir and celecoxib designed to synergistically suppress herpes virus replication, with the end goal of reducing virally promoted disease symptoms.

Contact Information

Headquarters

44 Milton AvenueALPHARETTA, GA, United States 30009

Phone

---

Fax

---

Executives

Chairman of the Board, Chief Executive Officer

Gregory Duncan

Chief Financial Officer

Angela Walsh

Senior Vice President of Operations

Ralph Grosswald

Chief Medical Officer

R. Michael Gendreau

Director

Melvin Toh